(Page 2 of 2)
pulled in $900,000 in equity funding, according to a regulatory filing last June.
—BioSphere Medical, a Rockland, MA-based developer of treatments for tumors, vascular malformations, and uterine fibroids, said it is being acquired by Utah-based Merit Medical Systems, for $96 million in cash. Merit (NASDAQ: MMSI) is paying $4.38 per share for BioSphere (NASDAQ: BSMD) common stock, a 54 percent premium over its closing price on May 12, the day before the agreement was announced. We profiled BioSphere back in October 2008.
—Stemgent, a company with offices in San Diego and Cambridge that makes consumable materials for stem cell research, pulled in $5.6 million of a planned $10.1 million equity round, which includes the conversion of some debt financing into equity stakes.
— Laparoscopic instrument maker Cambridge Endoscopic Devices wrapped up $3 million of a $7.5 million equity-based offering, from one investor, according to an SEC filing.
—Data protection and recovery software maker Double-Take Software, (NASDAQ: DBTK), announced it will be acquired by Vision Solutions in a deal with a net value of about $242 million. Vision, which is a portfolio company of private equity firm Thoma Bravo, will pay $10.55 per share for Southborough, MA-based Double-Take’s common stock, which represents a 21 percent premium over the $8.71 closing price the last business day before the company’s board expressed interest in an acquisition.
By posting a comment, you agree to our terms and conditions.